MOREPENLAB.NS
Strong BuyPremium GrowerAI neutralMorepen Laboratories Limited · Healthcare · India · $666M
INR 143.96 +6.4% · close 6 Oct · scored 7 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Morepen Laboratories is an Indian maker of active pharmaceutical ingredients, diagnostic devices and over-the-counter products. The shares have had very strong price momentum, but valuation is now demanding. Much of the business is generic ingredients, where pricing power is limited and competition from China is intense. There is no company-specific news here that explains the momentum or shows a durable competitive advantage.
ABOUT MOREPEN LABORATORIES LIMITED
Read
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 14.1B | 16.8B | 18.0B | 18.0B | 8.4% | 19.5B |
| EPS (INR) | 0.77 | 1.88 | 2.20 | 1.73 | 31.0% | 2.55 |
| Shares | 511.2M | 511.2M | 548.0M | 548.0M | +7.2% | 548.0M |
| Debt | 251.6M | 290.0M | 1.1B | 2.1B | 102.1% | 2.1B |
| Equity | 7.5B | 8.5B | 11.6B | 12.5B | 18.3% | — |
| Op CF | -911.7M | 733.7M | 320.6M | 326.4M | -33.3% | 330.9M |
| Inv CF | -465.1M | -833.0M | -3.2B | -1.2B | — | — |
| Fin CF | 1.4B | 52.0M | 3.0B | 974.0M | — | — |
Swung more than 72% of stocks we rank over the past year (57% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MOREPENLAB.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MOREPENLAB.NS | Morepen Laboratories Limited(you) | $666M | 85 | Strong Buy |
| BLISSGVS.NS | Bliss GVS Pharma Limited | $761M | 86 | Strong Buy |
| SPARC.NS | Sun Pharma Advanced Research Company Limited | $690M | 89 | Strong Buy |
| IOLCP.NS | IOL Chemicals and Pharmaceuticals Limited | $622M | 90 | Strong Buy |
| FDC.NS | FDC Limited | $587M | 78 | Buy |
| VIYASH.NS | Viyash Scientific Limited | $1.1B | 85 | Strong Buy |
| RPGLIFE.NS | RPG Life Sciences Limited | $500M | 80 | Buy |
| UNICHEMLAB.NS | Unichem Laboratories Limited | $406M | 88 | Strong Buy |
| AARTIDRUGS.NS | Aarti Drugs Limited | $416M | 82 | Strong Buy |
| PGHL.NS | Procter & Gamble Health Limited | $937M | 92 | Strong Buy |
Peer medians: ROE 11.9% · P/E 42.9x · Gross margin 59.4%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.